Engineered immune cells take aim at a common cancer target in Hard-to-Treat tumors
Disease control
Recruiting now
This early study tests a new treatment called SUV2208A, which uses a patient's own immune cells (T cells) that have been modified in a lab to recognize and attack cancer cells carrying a protein called CLDN18.2. The trial enrolls up to 18 adults with advanced solid tumors that ha…
Phase: EARLY_PHASE1 • Sponsor: Celest Therapeutics (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jul 03, 2026 19:22 UTC